Neurobiological adaptations to psychostimulants and opiates as a basis of treatment development

Annals of the New York Academy of Sciences

Volumn 909, Issue , 2000, Pages 51-87

  Sevarino, Kevin A ^a,b   Oliveto, Alison ^a   Kosten, Thomas R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA Healthcare Systems Connecticut   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; BUPRENORPHINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; KAPPA OPIATE RECEPTOR; MAZINDOL; METHADONE; METHYLPHENIDATE; MU OPIATE RECEPTOR; NEUROTRANSMITTER; OPIATE; PERGOLIDE MESILATE; PSYCHOSTIMULANT AGENT; SEROTONIN;

CONFERENCE PAPER; DRUG DEPENDENCE; LOCUS CERULEUS; NEUROBIOLOGY; NEUROTRANSMISSION; NORADRENERGIC NERVE; OPIATE ADDICTION; SIDE EFFECT;

EID: 0033941939     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06676.x     Document Type: Conference Paper

References (283)

1. 1. NATIONAL INSTITUTE ON DRUG ABUSE. 1993. National Household Survey on Drug Abuse: Population Estimates 1992. U.S. Government Printing Office, Rockville, MD.
2. 2. ANTHONY, J.C., A.M. ARRIA & E.O. JOHNSON. 1995. Epidemiological and public health issues for tobacco, alcohol, and other drugs. American Psychiatric Press Review of Psychiatry. J.M. Oldham & M.B. Riba, Eds. American Psychiatric Press, Washington, DC 14: 15-49.
3. 3. JOHANSON, C.E. & C.R. SCHUSTER. 1995. In Psychopharmacology: The Fourth Generation of Progress. F.E. Bloom & D.J. Kupfer, Eds. :1685-1697. Raven Press Ltd. New York.
4. 4. DICHIARA, G. & R.A. NORTH. 1992. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13: 185-193.
5. 5. WODAK, A. 1994. Managing illicit drug use: a practical guide. Drugs 47: 446-457.
6. 6. NOVICK, D.M., H. JOSEPH, T.S. CROXSON, E.A. SALSITZ, G. WANG, B.L. RICHMAN, L. PORETSKY, J.B. KEEFE & E. WHIMBEY. 1990. Absence of antibody to Human Immunodeficiency Virus in long-term, socially rehabilitated methadone maintenance patients. Arch. Internal Med. 150: 97-99.
7. 7. BERTSCHY, G. 1995. Methadone maintenance treatment: an update. Eur. Arch. Psychiatry Clin. Neurosci. 245: 114-124.
8. 8. ZWEBEN, J.E. & J.T. PAYTE. 1990. Methadone maintenance in the treatment of opioid dependence: a current perspective. West. J. Med. 152: 588-599.
9. 9. JOHANSON, C.E. & M.M. FISCHMAN. 1989. The pharmacology of cocaine related to its abuse. Pharmacology Rev. 41: 3-52.
10. 10. KOOB, G.F., R. MALDONADO & L. STINUS. 1992. Neural substrates of opiate withdrawal. Trends Neurosci. 15: 186-191.
11. 11. RITZ, M.C., R.J. LAMB, S.R. GOLDBERG & M.J. KUHAR. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
12. 12. BUNNEY, B.S. & G.K. AGHAJANIAN. 1978. D-amphetamine-induced depression of central dopamine neurons: evidence for mediation by both autoreceptors and a striatonigral feedback pathway. Naunyn Schmiedebergs Arch. Pharmacol. 304: 255-261.
13. 13. GIROS, B., M. JABER, S.R. JONES, R.M. WIGHTMAN & M.G. CARON. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (Lond.) 379: 606-612.
14. 14. FIBIGER, H.C., G.A. PHILLIPS & E.E. BROWN. 1992. The neurobiology of cocaine-induced reinforcement. Ciba Found. Symp. 166: 96-124.
15. 15. CHIUEH, C.C. & K.E. MOORE. 1974. In vivo evoked release of endogenously synthesized catecholamines from the cat brain evoked by electrical stimulation and D-amphetamine. J. Neurochem. 23: 159-168.
16. 16. BAXTER, B.L., M.I. GLUCKMAN, L. STEIN & R.A. SCERNI. 1974. Self-injection of apomorphine in the rat. Pharmacol. Biochem. Behav. 2: 387-391.
17. 17. WOOLVERTON, W.L., L.I. GOLDBERG & J.Z. GINOS. 1984. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J. Pharmacol. Exp. Ther. 230: 678-683.
18. 18. YOKEL, R.A. & R.A. WISE. 1978. Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology 58: 282-296.
19. 19. DAVIS, W.M. & S.G. SMITH. 1975. Effect of halperidol on (+)-amphetamine self-adminislration. J. Pharmacother. Pharmacol. 27: 540-542.
20. 20. DEWIT, H. & R.A. WISE. 1977. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can. J. Psychology 31: 195-203.
21. 21. KOOB, G.F. 1992. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13: 177-184.
22. 22. LACOSTA, S. & D.C. ROBERTS. 1993. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol. Biochem. Behav. 44: 161-165.
23. 23. LYNESS, W.H., N.M. FRIEDLE & K.E. MOORE. 1979. Destruction of dopaminergic nerve terminals in nucleus accumbens: effect of D-amphetamine self-administration. Pharmacol. Biochem. Behav. 11: 663-333.
24. 24. ROBERTS, D.C.S. & G.F. KOOB. 1982. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol. Biochem. Behav. 17: 901-904.
25. 25. ROBERTS, D.C.S., M.E. CORCORAN & H.C. FIBIGER. 1977. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 6: 615-620.
26. 26. HENRY, D.J., M.A. GREEN & F.J. WHITE. 1989. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: repeated administration. J. Pharmacol. Exp. Ther. 251: 833-839.
27. 27. PIERCE, R.C., P. DUFFY & P.W. KALIVAS. 1995. Sensitization to cocaine and dopamine autoreceptor subsensitivity in the nucleus accumbens. Synapse 20: 33-36.
28. 3H]WIN 35,428 binding in rabbit caudate nucleus after repeated injections of cocaine. Pharmacol. Biochem. Behav. 52: 335-340.
29. 29. HITRI, A. & R.J. WYATT. 1993. Regional differences in rat brain dopamine transporter binding: function of time after chronic cocaine. Clin. Neuropharmacol. 16: 525-539.
30. 30. DACKIS, C.A. & M.S. GOLD. 1985. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci. Biobehav. Rev. 9: 469-477.
31. 31. KRANZLER, H.R. & D.J. WALLINGTON. 1989. Prolactin, cocaine dependence and treatment. APA Annual Meeting Abstracts 1989.
32. 32. GAWIN, F.H. & E.H. ELLINWOOD. 1988. Cocaine and other stimulants: actions, abuse and treatment. New Engl. J. Med. 318: 1173-1181.
33. 33. SWARTZ, C.M., K. BREEN & F. LEONE. 1990. Serum prolactin levels during extended cocaine abstinence. Am. J. Psychiatry 147: 777-779.
34. 34. WEISS, F.Y., Y.L. HURD, M.A. UNGERSTEDT, P.M. PLOTSKY & G.F. KOOB. 1992. Neurochemical correlates of cocaine and ethanol self-administration. Ann. N.Y. Acad. Sci. 654: 220-241.
35. 35. KUMOR, K., M. SHERER & J. JAFFE. 1989. Effects of bromocriptine pretreatment on subjective and physiological responses to IV cocaine. Pharmacol. Biochem. Behav. 33: 829-837.
36. 36. PRESTON, K.L., J.T. SULLIVAN, E.C. STRAIN & G.E. BIGELOW. 1992. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J. Pharmacol. Exp. Ther. 262: 279-291.
37. 37. DACKIS, C.A., M.S. GOLD, D.R. SWEENEY, J.R. BYRON & R. CLIMKO. 1987. Single-dose bromocriptine reverses cocaine craving. Psychiatry Res. 20: 261-264.
38. 38. GIANNINI, A.J., P. BAUMGARTEL & L.R. DIMARZIO. 1987. Bromocriptine therapy in cocaine withdrawal. J. Clin. Pharmacol. 27: 267-270.
39. 39. TENNANT, F.S. & A. SAGHERIAN. 1987. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Internal Med. 147: 109-112.
40. 40. TURNER, T.H., J.C. COOKSON, J.A.H. WASS, P.L. DRURY, P.A. PRICE & G.M. BESSER. 1984. Psychotic reactions during treatment of pituitary tumors with dopamine agonists. Brit. Med. J. 289: 1101-1103.
41. 41. MOSCOVITZ, H., D. BROOKOFF & L. NELSON. 1993. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J. Gen. Internal Med. 8: 1-4.
42. 42. MONTOYA, I., K. PRESTON, E. CONE, R. ROTHMAN & D.A. GORELICK. 1994. Safety and efficacy of bupropion in combination with bromocriptine for treatment of cocaine dependence. Neuropsychopharmacology 10: 129S.
43. 43. MONTOYA, I., K.L. PRESTON, E.J. CONE, R. ROTHMAN & D.A. GORELICK. 1994. Combination of bupropion and bromocriptine for treatment of cocaine dependence. 1994 CPDD Annual Scientific Meeting Abstracts.
44. 44. HARDMAN, L., E. LIMBIRD, P.B. MOLINOEF, R.W. RUDDON & A.G. GILMAN, Eds. 1996. The Pharmacological Basis of Therapeutics. McGraw-Hill. New York.
45. 45. MALCOLM, R., B.R. HUTTO, J.D. PHILLIPS & J.C. BALLENGER. 1991. Pergolide mesylate treatment of cocaine withdrawal. J. Clin. Psychiatry 52: 39-40.
46. 46. MALCOLM, R., J.W. MOORE, D.K. KAJDASZ & C.E. COCHRANE. 1997. Pergolide mesylate. adverse events occurring in the treatment of cocaine dependence. Am. J. Addiction 6: 117-123.
47. 47. HANDELSMAN, L., P.L. CHORDIA, I.M. ESCOVAR, I.J. MARION & J.H. LOWINSON. 1988. Amantadine for treatment of cocaine dependence in methadone-maintained patients (letter). Am. J. Psychiatry 145: 533.
48. 48. ALTERMAN, A.I., M. DROBA, R.E. ANTELO, J.W. CORNISH, K.K. SWEENEY, G.A. PARIKH & C.P. O'BRIEN. 1992. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend. 31: 19-29.
49. 49. KOSTEN, T.R., C.M. MORGAN, J. FALCIONI & R.S. SCHOTTENFELD. 1992. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry 49: 894-899.
50. 50. WEDDINGTON, W.W., B.S. BROWN, C.A. HAERTZEN, J.M. HESS, J.R. MAHAFFEY, A.F. KOLAR & J.H. JAFFE. 1991. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse 17: 137-152.
51. 51. SHOLAR, M.B., S.E. LUKAS, E. KOURI & J.H. MENDELSON. 1994. Acute and chronic amantadine pre-treatment attenuates some of cocaine's effect in human subjects. NIDA Res. Monogr. 141: 431.
52. 52. ROTHMAN, R.B. 1990. High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development. Life Sciences 46: 17-21.
53. 53. BERGER, P., F. GAWIN & T.R. KOSTEN. 1989. Treatment of cocaine abuse with mazindol. Lancet 1(8632): 283.
54. 54. SEIBYL, J.P., L. BRENNER, J.H. KRYSTAL, R. JOHNSON & D.S. CHARNEY. 1992. Mazindol and cocaine addiction in schizophrenia (letter). Biol. Psychiatry 31: 1179-1181.
55. 55. KOSTEN, T.R., M. STEINBERG & I.A. DIAKOGIANNIS. 1993. Cross-over trial of mazindol for cocaine dependence. Am. J. Addiction 2: 161-164.
56. 56. MARGOLIN, A., S.K. AVANTS & T.R. KOSTEN. 1995. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am. J. Drug Alcohol Abuse 21: 469-481.
57. 57. STINE, S. & T.R. KOSTEN. 1992. Use of drug combinations in treatment of opioid withdrawal. J. Clin. Psycopharmacol. 12: 203-209.
58. 58. STINE, S.M., J.H. KRYSTAL, T.R. KOSTEN & D.S. CHARNEY. 1995. Mazindol treatment for cocaine dependence. Drug Alcohol Depend. 39: 245-252.
59. 59. PRESTON, K.L., J.T. SULLIVAN, P. BERGER & G.E. BIGELOW. 1993. Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J. Pharmacol. Exp. Ther. 267: 296-307.
60. 60. KOSTEN, T.R. & E. MCCANCE-KATZ. 1995. In Review of Psychiatry. J. Oldham & M. Riba, Eds. :105-126. American Psychiatric Press.
61. 61. KHANTZIAN, E.J., F. GAWIN, H.D. KLEBER & C.E. RIORDAN. 1984. Methylphenidate (ritalin) treatment of cocaine dependence: a preliminary report. J. Subs. Abuse Treat. 1: 107-112.
62. 62. GAWIN, F.H., C.A. RIORDAN & H.D. KLEBER. 1985. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative study. Am. J. Drug Alcohol Abuse 11: 193-197.
63. 63. GRABOWSKI, J., J.D. ROACHE, J.M. SCHMITZ, H. RHOADES, D. CRESON & A. KORSZUN. 1997. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17: 485-488.
64. 64. SHERER, M.A., K.M. KUMOR & J.H. JAFFE. 1989. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 27: 117-125.
65. 65. GAWIN, F.H., M.E. KHALSA, J. BROWN & P. JATLOW. 1993. Flupenthixol treatment of crack users: initial double-blind results. NIDA Res. Monogr. 132: 319.
66. 66. KHALSA, E.K., P. JATLOW & F. GAWIN. 1994. Flupenthixol and desipramine treatment of crack users: double blind results. NIDA Res. Monogr. 141: 439.
67. 67. KOSTEN, T.A., M.J.D. MISERENDINO, D.W. MARBY & E.J. NESTLER. 1994. Chronic haloperidol enhances cocaine conditioned place preference. NIDA Res. Monogr. 141: 13.
68. 68. LEDUC, P.A. & G. MITTLEMAN. 1993. Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology 110: 427-436.
69. 69. SCHNEIER, F.R. & S.G. SIRIS. 1987. A review of psychoactive substance use and abuse in schizophrenia, patterns of drug choice. J. Nervous Mental Dis. 175: 641-652.
70. 70. GAWIN, F.H. & H.D. KLEBER. 1986. Pharmacological treatment of cocaine abuse. Psychiatric Clinics N. A. 9: 573-583.
71. 71. TENNANT, F.S. & R.A. RAWSON. 1982. Cocaine and amphetamine dependence treated with desipramine. NIDA Res. Monogr. 43: 351-355.
72. 72. GAWIN, F.H., H.D. KLEBER, R. BYCK, B.J. ROUNSAVILLE, T.R. KOSTEN, P.I. JATLOW & C. MORGAN. 1989. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 46: 117-121.
73. 73. LEVIN, F.R. & A.F. LEHMAN. 1991. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J. Clin. Psychopharmacol. 11: 374-378.
74. 74. WEISS, R.D. 1988. Relapse to cocaine after initiating desipramine treatment. JAMA 260: 2545-2546.
75. 75. COVI, L., I.D. MONTOYA, J.M. HESS & N. KREITER. 1993. Desipramine for treatment of cocaine dependence: randomized, double-blind, placebo-controlled study. ACNP Annual Meeting Abstracts p. 173.
76. 76. COVI, L., I.D. MONTOYA, J.M. HESS & N. KREITER. 1994. Double-blind comparison of desipramine and placebo for treatment of cocaine dependence. 1994 CPDD Annual Scientific Meeting Abstracts.
77. 77. CARROLL, K.M., B.J. ROUNSAVILLE, L.T. GORDON, C. NICH, P. JATLOW, R.M. BISIGHINI & F.H. GAWIN. 1994. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Arch. Gen. Psychiatry 51: 177-187.
78. 78. OLIVETO, A., A. FEINGOLD, R. SCHOTTENFELD, P. JATLOW & T.R. KOSTEN. 1999. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch. Gen. Psychiatry 56: 812-820.
79. 79. ROSECAN, J. 1983. The treatment of cocaine abuse with imipramine, L-tyrosine, and L-tryptophan. 7th World Congress of Psychiatry, Vienna, Austria (1983).
80. 80. NUNES, E.V., F.M. QUITKIN, R. BRADY & J.W. STEWART. 1991. Imipramine treatment of methadone maintenance patients with affective disorder and illicit drug use. Am. J. Psychiatry 148: 667-669.
81. 81. ZIEDONIS, D.M. & T.R. KOSTEN. 1991. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J. Psychoactive Drugs 23: 417-425.
82. 82. RITZ, M.C. & M.J. KUHAR. 1989. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J. Pharmacol. Exp. Ther. 248: 1010-1017.
83. 83. CUNNINGHAM, K.A., J.M. PARIS & N.E. GOEDERS. 1992. Serotonin neurotransmission in cocaine sensitization. Ann. N.Y. Acad. Sci. 654: 117-127.
84. 84. PRADHAN, S.N., A.K. BATTACHARYA & S. PRADHAN. 1978. Serotonergic manipulation of the behavioral effects of cocaine in rats. Commun. Psychopharmacol. 2: 481-486.
85. 85. BATKI, S.L., L.B. MANFREDI, P. JACOB & R.T. JONES. 1993. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J. Clin. Psychopharmacol. 13: 243-250.
86. 86. POLLACK, M.H. & J.F. ROSENBAUM. 1991. Fluoxetine treatment of cocaine abuse in heroin addicts. J. Clin. Psychiatry 52: 31-33.
87. 87. COVI, L., J.M. HESS, N.A. KREITER & C.A. HAERTZEN. 1995. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers. Am. J. Drug Alcohol Abuse 21: 327-344.
88. 88. GRABOWSKI, J., H. RHOADES, R. ELK, J. SCHITZ, C. DAVIS, D. CRESON & K. KIRBY. 1995. Fluoexetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials. J. Clin. Psychopharmacol. 15: 163-174.
89. 89. OLIVETO, A.H., T.R. KOSTEN, R.S. SCHOTTENFELD, J. FALCIONI & D. ZIEDONIS. 1995. Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. J. Subs. Abuse Treat. 12: 423-428.
90. 90. WALSH, S.L., K.L. PRESTON, J.T. SULLIVAN & G.E. BIGELOW. 1992. Fluoxetine attenuates the effects of intravenous cocaine in humans. ACNP Annual Meeting Abstracts p. 230.
91. 91. WALSH, S.L., J.T. SULLIVAN & G.E. BIGELOW. 1994. Fluoxetine effects on cocaine responses: a double-blind laboratory assessment in humans. 1994 CPDD Annual Scientific Meeting Abstracts.
92. 92. WASHBURN, A.M., S.L. BATKI, K. DELUCCI, J. MURPHY, T.A. JONES & N. NANDA. 1994. Predictors of outcome in a clinical trial of fluoxetine treatment of primary cocaine dependence. NIDA Res. Monogr. 141: 139.
93. 93. BATKI, S.L., L.B. MANFREDI, P. JACOB, 3RD & R.T. JONES. 1994. Fluoxetine in primary and secondary cocaine dependence: outcome quantitative benzoylecgonine concentration. NIDA Res. Monogr. 141: 140.
94. 94. KOSTEN, T.R., T. A. KOSTEN, F.H. GAWIN, L.T. GORDON, I. HOGAN & H.D. KLEBER. 1992. An open trial of sertraline for cocaine abuse. Am. J. Addictions 1: 349-353.
95. 95. SMALL, G.W. & J.J. PURCELL. 1985. Trazodone and cocaine abuse (letter). Arch. Gen. Psychiatry 42: 524.
96. 96. MARGOLIN, A., T.A. KOSTEN, I. PETRAKIS, S.K. AVANTS & T.R. KOSTEN. 1991. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen. Psychiatry 48: 87.
97. 97. SINGHA, A., A. OLIVETO & E. MCCANCE. 1997. Effects of cocaine prior to and during bupropion maintenance in cocaine abusers. 59th Annual Scientific Meeting of the College on Problems of drug dependence, Nashville, TN.
98. 98. MARGOLIN, A., T.R. KOSTEN, S.K. AVANTS, J. WILKINS, W. LING, M. BECKSON, I.O. ARNDT, J. CORNISH, J.A. ASCHER, S.H. LI, et al. 1995. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Dependence 49: 125-131.
99. 99. VOCCI, F., T.N. ALIM, R.B. ROSSI & T. LINDQUEST. 1994. The development of pharmacotherapy for cocaine addiction: bupropion as a case study. 1994 CPDD Annual Scientific Meeting Abstracts p. 26.
100. 100. HABERNY, K.A., S.L. WALSH, D. GINN & G.E. BIGELOW. 1994. Interaction of selegiline and cocaine in human cocaine abusers. 1994 CPDD Annual Scientific Meeting Abstracts.
101. 101. HALIKAS, J.A., R.D. CROSBY, G.A. CARLSON, F. CREA & N.M. GRAVES, L.D. BOWERS. 1991. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short-term, double-blind crossover design. Clin. Pharmacol. Ther. 50: 81-95.
102. 102. HALIKAS, J., K. KUHN, G. CARLSON, F. CREA & R. CROSBY. 1992. The effect of carbamazepine on cocaine use. Am. J. Addiction 1: 129-139.
103. 103. HATSUKAMI, D., R. KEENAN, J. HALIKAS, P.R. PENTEL & L.H. BRAUER. 1991. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology 104: 120-124.
104. 104. HALIKAS, J.A., R.D. CROSBY, V.L. PEARSON, N.M. GRAVES, S.M. NUGENT & G.A. CARLSON. 1993. Carbamazepine improves early cocaine treatment retention and treatment effectiveness. ACNP Annual Meeting Abstracts p. 175.
105. 105. MONTOYA, I.D., F.R. LEVIN, P.J. FUDALA & D.A. GORELICK. 1993. Double-blind study with carbamazepine for treatment of cocaine dependence. ACNP Annual Meeting Abstracts p. 173.
106. 106. KRANZLER, H.R. & L.O. BAUER. 1993. Carbamazepine for cocaine dependence. ACNP Annual Meeting Abstracts p. 175.
107. 107. CORNISH, J.W., I. MAANY, P.J. FUDALA, S. NEAL, S.A. POOLE, P. VOLPICELLI & C.P. O'BRIEN. 1995. Carbamazepine treatment for cocaine dependence. Drug Alcohol Dependence 38: 221-227.
108. 108. KRANZLER, H.R., L.O. BAUER, D. HERSH & V. KLINGHOFFER. 1995. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Dependence 38: 203-211.
109. 109. MONTOYA, I.D., F.R. LEVIN, P.J. FUDALA & D.A. GORELICK. 1995. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Dependence 38: 213-219.
110. 110. MELLO, N.K., J.B. KAMIEN, J.H. MENDELSON & S.E. LUKAS. 1991. Effects of naltrexone on cocaine self-administration by rhesus monkey. NIDA Res. Monogr. 105: 617-618.
111. 111. KOSTEN, T.R., D.G. SILVERMAN, J. FLEMING, T.A. KOSTEN, F. GAWIN, M. COMPTON, P. JATLOW & R. BYCK. 1992. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol. Psychiatry 32: 543-548.
112. 112. SILVERMAN, D.G., T.R. KOSTEN, J. FLEMING, T.A. KOSTEN, F.H. GAWIN, M. COMPTON, P. JATLOW & R. BYCK. 1992. Intravenous cocaine challenges during naltrexone maintenance. NIDA Res. Monograph 132: 338.
113. 113. WALSH, S.L., J.T. SULLIVAN, K.L. PRESTON & G.E. BIGELOW. 1994. Naltrexone interactions with cocaine, hydromorphone, and a "speedball" combination in substance abusers. NIDA Res. Monogr. 141: 26.
114. 114. CARROLL, K., D. ZIEDONIS, S.O'MALLEY, E. MCCANCE-KATZ, L. GORDON & B. ROUNSAVILLE. 1993. Pharmacologic interventions for abusers of alcohol and cocaine: disulfiram versus naltrexone. Am. J. Addictions 2: 77-79.
115. 115. FUDALA, P.J., J.H. JAFFE, E.M. DAX & R.E. JOHNSON. 1990. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 47: 525-34.
116. 116. JOHNSON, R.E., J.H. JAFFE & P.J. FUDALA. 1992. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267: 2750-2755.
117. 117. KOSTEN, T.R., H.D. KLEBER & C. MORGAN. 1989. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44: 887-92.
118. 118. OLIVETO, A.H., T.R. KOSTEN, R. SCHOTTENFELD, D. ZIEDONAS & J. FALCIONE. 1994. Cocaine use in buprenorphine- vs methadone-maintained cocaine users. Am. J. Addictions 3: 43-18.
119. 119. MCCANCE-KATZ, E.F., L.H. PRICE, C.J. MCDOUGLE, T.R. KOSTEN, J.E. BLACK & P.I. JATLOW. 1993. Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene. Psychopharmacology 111: 39-46.
120. 120. HAMEEDI, F.A., M.I. ROSEN, E.F. MCCANCE-KATZ, T.J. MCMAHON, L.H. PRICE, P.I. JATLOW, S.W. WOODS & T.R. KOSTEN. 1995. Behavioral, physiological and pharmacological interaction of cocaine and disulfiram. Biol. Psychiatry 37: 560-563.
121. 121. VAN ETTEN, M.L., S.T. HIGGINS, A.J. BUDNEY, W.K. BICKEL, J.R. HUGHES & F. FOERG. 1994. Disulfiram therapy in patients abusing cocaine and alcohol. NIDA Res. Monogr. 141: 443.
122. 122. MCCANCE-KATZ, E.F., L.H. PRICE, T.R. KOSTEN, F. HAMEEDI, M.I. ROSEN & P.I. JATLOW. 1993. Pharmacology, physiology and behavioral effects of cocaethylene in humans. ACNP Annual Meeting Abstracts p. 237.
123. 123. ACRI, J.B., B. SEIDLECK & J.M. WITKIN. 1994. Effects of dopamine uptake inhibitors on behavioral and toxic effects of cocaine. NIDA Res. Monograph 141: 441.
124. 124. CHAR, G.U., M.H. BAUMANN, C.I.-T. CHEN, K.C. RICE, B.R. DE COSTA, D. MATECKA & R.B. ROTHMAN. 1994. The cocaine-induced rise in extracellular dopamine in the nucleus accumbens is reduced by GBR-12909 pretreatment. NIDA Res. Monogr. 141: 122.
125. 125. GLOWA, J.R., F.H. WOJNICKI, B. DE COSTA, D. MATECKA, K.C. RICE & R.B. ROTHMAN. 1994. The effects of GBR-12909 on responding of rhesus monkeys maintained under schedules of cocaine and food delivery. NIDA Res. Monogr. 141: 12.
126. 126. SULLIVAN, J.T., M.P. TESTA, K.L. PRESTON, P. BLUM & D.R. JASINSKI. 1994. Psychoactivity of ritanserin and its interaction with intravenous cocaine. NIDA Res. Monogr. 141: 377.
127. 127. KOSTEN, T.A. & E. NESTLER. 1994. Clozapine attenuates cocaine conditioned place preference. Life Sci. 55: 9-14.
128. 128. HEIDBREDER, C. & T.S. SHIPPENBERG. 1994. Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. 1994 CPDD Annual Scientific Meeting Abstracts.
129. 129. SEPINWALL, J., G.P. VINCENT & S. WILLIAMS. 1992. Differential profiles of NMDA, 5-HT3 and D1 and D2 antagonists as antagonists of the stimulant actions of cocaine in mice. ACNP Meeting Abstracts p. 224.
130. 130. MARGOLIN, A., S.K. AVANTS, D. DEPHILIPPIS & T.R. KOSTEN. 1998. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am. J. Drug Alcohol Abuse 24: 85-101.
131. 123I] bela-CIT SPECT. Am. J. Psychiatry 155: 832-834.
132. 132. VOLKOW, N.D., J.S. FOWLER, A.P. WOLF, D. SCHLYER, C.Y. SHINE, R. ALPERT, S.L. DEWEY, J. LOGAN, B. BENDRIEM & D. CHRISTMAN. 1990. Effect of chronic cocaine abuse on postsynaptic dopamine receptors. Am. J. Psychiatry 147: 719-724.
133. 133. VOLKOW, N.D., G.J. WANG, J.S. FOWLER, J. LOGAN, R. HITZEMANNN, S.J. GATLEY, R.R. MACGREGOR & A.P. WOLF. 1996. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14: 159-168.
134. 134. HOLMAN, B.L., J. MENDELSON, B. GARADA, S.K. TEOH, E. HALLGRING, K.A. JOHNSON & N.K. MELLO. 1993. Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. J. Nuclear Med. 34: 723-727.
135. 135. HOLMAN, B.L., P.A. CARVALO, J. MENDELSON, S.K. TEOH, R. NARDIN, E. HALLGRING, N. HEBBEN & K.A. JOHNSON. 1991. Brain perfusion is abnormal in cocaine dependent polydrug users: A study using Tc-99m-HMPAO and ASPECT. J. Nuclear Med. 32: 1206-1210.
136. 136. LEVIN, J.M. & M.J. KAUFMAN. 1995. Functional studies in substance abuse: imaging and beyond. J. Nuclear Med. 36: 1298-1300.
137. 137. LEVIN, J.M., B.L. HOLMAN, J.H. MENDELSON, S.K. TEOH, B. GARADA, K.A. JOHNSON & S. SPRINGER. 1994. Gender differences in cerebral perfusion in cocaine abuse: Technetium-99m-HMPAO SPECT study of drug-abusing women. J. Nuclear Med. 35: 1902-1909.
138. 138. STRICKLAND, T.L., I. MENA, J. VILLANUEVA-MEYER, B.L. MILLER, J. CUMMINGS, C.M. MEHRINGER, P. SATZ & H.J. MYERS. 1993. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J. Neuropsychiatry Clin. Psychiatry 5: 419-427.
139. 139. VOLKOW, N.D., J.S. FOWLER, A.P. WOLF, R. HITZEMANN, S. DEWEY, B. BENDRIEM, R. ALPERT & A. HOFF. 1991. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry 148(5): 621-626.
140. 140. VOLKOW, N.D., N. MULLANI, L. GOULD, S. ADLER & K. KRAJEWSKI. 1988. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br. J. Psychiatry 152: 641-648.
141. 141. WEBER, D.A., D. FRANCESCHI, M. IVANOVIC, H.L. ATKINS, C. CABAHUG, C.T. WONG & H. SUSSKIND. 1993. SPECT and planar brain imaging in crack abuse: iodine-123-iodoamphetamine uptake and localization. J. Nuclear Med. 34: 899-907.
142. 142. ARDILA, A., M. ROSSELLI & S. STRUMWASSER. 1991. Neuropsychological deficits in chronic cocaine abusers. Int. J. Neurosci. 57: 73-79.
143. 143. BERRY, J., W.G. VAN GORP, D.S. HERZBERG, C. HINKIN, K. BOONE, L. STEINMAN & J.N. WILKINS. 1993. Neuropsychological deficits in abstinent cocaine abusers: preliminary findings after two weeks of abstinence. Drug Alcohol Dependence 32: 231-237.
144. 144. BEATTY, W.W., V.M. KATZUNG, V.J. MORELAND & S.J. NIXON. 1995. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Dependence 37: 247-253.
145. 145. HOFF, A.L., H. RIORDAN, L. MORRIS, V. CESTARO, M. WIENEKE, R. ALPERT, G.J. WANG & N. VOLKOW. 1996. Effects of crack cocaine on neurocognitive function. Psychiatry Res. 60(2-3): 167-176.
146. 146. O'MALLEY, S. & F.H. GAWIN. 1990. Abstinence symptomatology and neuropsychiatric impairment in chronic cocaine abuse. NIDA Res. Monogr. 101: 179-190.
147. 147. WOODS, S.W., S.S. O'MALLEY, B.L. MARTINI, C.J. MCDOUGLE, L.H. PRICE, J.H. KRYSTAL, P.B. HOFFER & T.R. KOSTEN. 1991. SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers. Prog. Neuro-psychopharmacol. Biol. Psychiatry 15: 649-662.
148. 148. WASHTON, A.M., M.S. GOLD & A.L. POTTASH. 1984. Survey of 500 callers to a national cocaine help-line. Psychosomatics 25: 771-775.
149. 149. RYLANDER, G. 1969. In Abuse of Central Stimulants. F. Sjoquist & M. Tootie, Eds. :251-274. Almquist and Wiksell. Stockholm
150. 150. GAWIN, F.H. & H.D. KLEBER. 1988. Evolving conceptualizations of cocaine dependence. Yale J. Biol. Med. 61: 123-136.
151. 151. O'MALLEY, S., M. ADAMSE, R.K. HEATON & F.H. GAWIN. 1992. Neuropsychological impairment in chronic cocaine abusers. Am. J. Drug Alcohol Abuse 18: 131-144.
152. 152. MANSCHRECK, T.C., M.L. SCHNEYER, C.C. WEISSTEIN, J. LAUGHERY, J. ROSENTHAL, T. CELADA & J. BERNER. 1990. Freebase cocaine and memory. Comp. Psychiatry 31: 369-375.
153. 153. SMELSON, D.A., A. ROY, S. SANTANA & C. ENGELHART. 1999. Neuropsychological deficits in withdrawn cocaine-dependent males. Am. J. Drug Alcohol Abuse 25(2): 377-381.
154. 154. MITTENBERG, W. & S. MOTTA. 1993. Effects of chronic cocaine abuse on memory and learning. Arch. Clin. Neuropsychol. 8: 447.
155. 155. FALS-STEWART, W., S. LUCENTE, T. SHANAHAN & L. BROWN. 1995. The relationship of patients' cognitive status and therapists' ratings of psychological distress among psychoactive substance users in long-term residential treatment. J. Subs. Abuse 7: 205-222.
156. 156. BAUER, L.O. 1993. Motoric signs of CNS dysfunction associated with alcohol and cocaine withdrawal. Psychiatry Res. 47: 69-77.
157. 157. ROBERTS, L.A. & L.O. BAUER. 1993. Reaction time during cocaine versus alcohol withdrawal: Longitudinal measures of visual and auditory suppression. Psychiatry Res. 46: 229-237.
158. 158. AZRIN, R.L., C. MILLSAPS, B. SCHNEIDER & W. MITTENBERG. 1995. Abstinent cocaine abusers' neuropsychological functioning on the SMW-R and WAIS-R [Abstract]. Arch. Clin. Neuropsychol. 9: 289.
159. 159. SELBY, M.J., R.L. AZRIN, S.J. IRELAND & J.K. MORENO. 1995. Differential recovery of neuropsychological functioning in alcohol, cocaine, and polysubstance abusers [Abstract]. Arch. Clin. Neuropsychol. 10: 390.
160. 160. LONDON, E.D., N.G. CASCELLA, D.F. WONG, R.L. PHILLIPS, R.F. DANNALS, J.M. LINKS, R. HERNING, R. GRAYSON, J.H. JAFEE & H.N. WAGNER. 1990. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose. Arch. Gen. Psychiatry 47: 567-574.
161. 161. WOLKIN, A., B. ANGRIST, A. WOLF, J. BRODIE, B. WOLKIN, J. JAEGER, R. CANCRO & J. ROTROSEN. 1987. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology 92: 241-246.
162. 162. PEARLSON, G.D., P.J. JEFFERY, G.J. HARRIS, C.A. Ross, M.W. FISCHMAN & E.E. CAMARGO. 1993. Correlation of acute cocaine induced changes in local cerebral blood flow with subjective effects. Am. J. Psychiatry 150: 495-497.
163. 163. TUMEH, S.S., J.S. NAGEL, R.J. ENGLISH, M. MOORE & B.L. HOLMAN. 1990. Cerebral abnormalities in cocaine abusers: Demonstration by SPECT perfusion brain scintigraphy. Work in progress. Radiology 176: 821-824.
164. 164. MENA, I., R. GIOMBETTI & C.K. CODY. 1990. Acute cerebral blood flow changes with cocaine intoxication. Neurology 40 (Suppl. 1): 179.
165. 165. STRICKLAND, T.L., I. MENA, J. VILLANUEVA-MEYER, B.L. MILLER, J. CUMMINGS, C.M. MEHRINGER, P. SATZ & H. MEYERS. 1993. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J. Neuropsychiatry Clin. Neurosci. 5(4): 419-427.
166. 166. MILLER, B.L., I. MENA, R. GIOMBETTI, J. VILLANUEVA-MEYER & A. H. DJENDEREDJIAN. 1992. Neuropsychiatric effects of cocaine: SPECT measurements. J. Addictive Disorders 11: 47-58.
167. 167. HOLMAN, B.L., B. GARADA, K.A. JOHNSON, J. MENDELSON, E. HALLGRING, S.K. TEOH, J. WORTH & B.A. NAVIA. 1992. A comparison of brain perfusion SPECT in cocaine abuse and AIDS dementia complex. J. Nuclear Med. 33: 1312-1315.
168. 168. VOLKOW, N.D., J.S. FOWLER, A.P. WOLF, R. HITZEMANN, S. DEWEY, B. BENDRIEM, R. ALPERT & A. HOFF. 1991. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry 148: 621-626.
169. 169. KOSTEN, T.R., C. CHEEVES, J. PALUMBO, J.P. SEIBYL, L.H. PRICE & S.W. WOODS. 1998. Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Dependence 50: 187-195.
170. 170. VOLKOW, N.D., R. HITZEMANN, G.H. WANG, R. HITZMAN, G.J. WANG, J.S. FOWLER, A.P. WOLF, S.L. DEWEY & L. HANDLESMAN. 1992. Long-term frontal brain metabolic changes in cocaine abusers. Synapse 11: 184-190.
171. 171. WALLACE, E.A., et al. 1994. Regional cerebral blood flow effects of acute cocaine infusion. NIDA Res. Monogr. 141: 325.
172. 172. PUPI, A., M.T.R. DECRISTOFARO, L. BACCIOTTINI, D. ANTONIUCCI, A.R. FORMICONI, M. MASCALCHI & U. MELDOLESI. 1991. An analysis of the arterial input curve for Te-99m-HMPAO: quantification of rCBF using single-photon emission computed tomography. J. Nuclear Med. 32: 1501-1506.
173. 173. SILVERMAN, D.G., T.R. KOSTEN, P.I. JATLOW, V. GUTTER, J. FLEMING, T.Z. O'CONNOR & R. BYCK. 1997. Decreased digital flow persists after the abatement of cocaine-induced hemodynamic stimulation. Anesthesia and Analgesia 84: 46-50.
174. 174. VITULLO, J.C., R. KARAM, N. MEKHAIL, P. WICKER, G.L. ENGELMANN & P.A. KHAIRALLAH. 1989. Cocaine-induced small vessel spasm in isolated rat hearts. Am. J. Pathol. 135: 85-91.
175. 175. HE, G.Q., A. ZHANG, B.T. ALTURA & B.M. ALTURA. 1994. Cocaine-induced cerebrovasospasm and its possible mechanism of action. J. Pharmacol. Exp. Ther. 268: 1532-1539.
176. 176. FLORES, E.D., R.A. LANGE, R.G. CIGARROA & L.D. HILLIS. 1990. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: enhanced vasoconstriction at sites of significant stenoses. J. Am. College Cardiol. 16: 74-79.
177. 177. MINOR, R.L., B.D. SCOTT, D.D. BROWN & M.D. WINNIFORD. 1991. Cocaine-induced myocardial infarction in patients with normal coronary arteries. Ann. Internal Med. 115: 797-806.
178. 178. KOLODGIE, F.D., R. VIRMANI, J.F. CORNHILL, E.E. HERDERICK & J. SMIALEK. 1991. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J. Am. College Cardiol. 17: 1553-1560.
179. 179. KLONER, R.A., S. HALE, K. ALKER & S. REZKALLA. 1992. The effects of acute and chronic cocaine use on the heart. Circulation 85: 407-419.
180. 180. DRESSLER, F.A., S. MALEKZADEH & W.C. ROBERTS. 1990. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am. J. Cardiol. 65: 303-308.
181. 181. OM, A., M. WARNER, N. SABRI, L. CECICH & G. VETROVEC. 1992. Frequency of coronary artery disease and left ventricle dysfunction in cocaine users. Am. J. Cardiol. 69: 1549-1552.
182. 182. TUCHMAN, A.J., M. DARAS, P. ZALZAL & J. MANGIARDI. 1987. Intracranial hemorrhage after cocaine abuse (letter). JAMA 257: 1175.
183. 183. LEVINE, S.R., J.M. WASHINGTON, M.F. JEFFERSON, S.W. KIERNAN, M. MEON, H. FEIT & K.M. WELSH. 1987. Crack cocaine-associated stroke. Neurology 37: 1849-1853.
184. 184. LEVINE, S.R., et al. 1991. A comparative study of the cerebrovascular complications of cocaine: Alkaloidal versus hydrochloride - a review. Neurology 41: 1173-1177.
185. 185. RINDER, H.M., K.A. AULT, P.I. JATLOW, T.R. KOSTEN & B.R. SMITH. 1994. Platelet alpha-granule release in cocaine users. Circulation 90: 1162-1167.
186. 186. ROSS, R., J. GLOMSET, B. KARIYA & L. HARKER. 1974. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl. Acad. Sci. USA 71: 1207-1210.
187. 187. ROSS, R. & A. VOGEL. 1978. The platelet-derived growth factor. Cell 14: 203-210.
188. 188. ROSS, R. 1986. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314: 488-494.
189. 189. KAPLAN, K.L., M.J. BROEKMAN, A. CHERNOFF, G.R. LESZNIK & M. DRILLINGS. 1979. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 53: 604-618.
190. 190. ANTIPLATELET TRIALISTS' COLLABORATION. 1988. Secondary Prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. J. 296: 320-331.
191. 191. ANTIPLATELET TRIALISTS' COLLABORATION. 1994. Collaborative overview of randomized trials of antiplatelet treatment. Part I: Prevention of death, myocardial function, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308: 81-106.
192. 192. ROTH, G.J. & D.C. CALVERLEY. 1994. Aspirin, platelets, and thrombosis: theory and practice. Blood 83: 885-898.
193. 193. MIYAMOTO, T., N. OGINO, S. YAMAMOTO & O. HAYAISHI. 1976. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 251: 2629-2636.
194. 194. OHKI, S., N. OGINO, S. YAMAMATO & O. HAYAISHI. 1979. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase. J. Biol. Chem. 254: 829.
195. 195. ROTH, G.J., E. T. MACHUGA & J. OZOLS. 1983. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 22: 4672-4675.
196. 196. ROTH, G.J., E.T. MACHUGA & P. STRITTMATTER. 1983. The heme-binding properties of prostaglandin synthease from sheep vesicular gland. J. Biol. Chem. 256: 10018-10022.
197. 197. FIELDS, W.E., N.A. LEMAK, R.F. FRANKOWSKI & R.J. HARDY. 1977. Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301-314.
198. 198. FIELDS, W.E., N.A. LEMAK, R.F. FRANKOWSKI & R.J. HARDY. 1978. Controlled trial of aspirin in cerebral ischemia, Part II. Stroke 9: 309-319.
199. 199. SORENSEN, P.S., H. PEDERSEN, H. PETERSSON, A. HELTBERG, N. SIMONSEN, O. MUNCK & L.A. ARDERSEN. 1983. Acetylsalicyclic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 14: 15-22.
200. 200. GOTTSCHALK, C.H., J. SEIBYL, H. RINDER & T.R. KOSTEN. 1998. Treatment of cocaine-related cerebral perfusion deficits with anti-platelet agents: SPM analyses of early abstinence. 1998 CPDD Abstracts 61: 54.
201. 201. SIFFET, W., S. GENGENBACH & P. SCHEID. 1986. Inhibition of platelet aggregation by amiloride. Thrombosis Res. 44: 235-240.
202. 202. RINDER, C.S., L.A. STUDENT, J.L. BONAN, H.M. RINDER & B.R. SMITH. 1993. Aspirin does not inhibit ADP-induced platelet α-granule release. Blood 82: 505-512.
203. 203. JOHNSON, B., B. BARRON, B. FANG, L. LAMKI, L. WAGNER, L. WELLS, P. KENNY, D. OVERTON, S. DHATLER, D. ABRAMSON, R. CHEN & L. KRAMER. 1998. Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study. Psychopharmacology (Berl.) 136: 335-341.
204. 204. SINGHA, A.K., E.F. MCCANCE-KATZ, I. PETRAKIS, K. SEVARINO, T.R. KOSTEN & A. OLIVETO. 1999. The effects of naltrexone and isradipine on the behavioral responses to cocaine in human subjects. 1999 CPDD Abstracts.
205. 205. LIPTON, S.A. & P.A. ROSENBERG. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330: 613-622.
206. 31P MR spectroscopy study. Mag. Res. Med. 35: 658-663.
207. 207. MUIR, K.W. & K.R. LEES. 1995. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513.
208. 208. MUNTANER, C., K.M. KUMOR, C. NAGOSHI & J.H. JAFFE. 1991. Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology (Berl.) 105: 37-41.
209. 209. CARRERA, M.R., J.A. ASHLEY, L.H. PARSONS, P. WIRSCHING, G.F. KOOB & K.D. JANDA. 1995. Suppression of psychoactive effects of cocaine by active immunization. Nature 378: 727-730.
210. 210. FOX, B.S., K.M. KANTAK, M.A. EDWARDS, K.M. BLACK, B.K. BALLINGER, A.J. BOTKA, T.L. FRENCH, T.L. THOMPSON, V.C. SCHOD, J.L. GREENSTEIN, M.L. GEFTER, M.A. EXLEY, P.A. SWAIN & T.J. BRINEI. 1996. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 2: 1129-1132.
211. 211. FOX, B.S. 1997. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Dependence 48: 153-158.
212. 212. SPARENBORG, S., F. VOCCI & S. ZUKIN. 1997. Peripherial cocaine-blocking agents: new medications for cocaine dependence. Drug Alcohol Dependence 48: 149-151.
213. 213. GORELICK, D.A. 1997. Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Dependence 48: 159-165.
214. 214. BOUDIN, H.M. 1972. Contingency contracting as a therapeutic tool in the deceleration of amphetamine use. Behav. Res. Ther. 3: 604-408.
215. 215. ANKER, A.L. & T.J. CROWLEY. 1982. Use of contingency contracts in specialty clinics for cocaine abuse. NIDA Res. Monogr. 41: 452-459.
216. 216. HIGGINS, S.T., D.D. DELANEY, A.J. BUDNEY, W.K. BICKEL, J.R. HUGHES, F. FOERG & J.W. FENWICK. 1991. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry 148: 1218-1224.
217. 217. HIGGINS, S.T., A.J. BUDNEY, W.K. BICKEL, J.R. HUGHES, F. FOERG & G. BADGER. 1993. Achieving cocaine abstinence with a behavioral approach. Am. J. Psychiatry 150: 763-769.
218. 218. HIGGINS, S.T., A.J. BUDNEY, W.K. BICKEL, F.E. FOERG, R. DONHAM & G.J. BADGER. 1994. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry 51: 568-576.
219. 219. SILVERMAN, K., S.T. HlGGINS, R.K. BROONER, I.D. MONTOYA, E.J. CONE, C.R. SCHUSTER, & K.L. PRESTON. 1996. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch. Gen. Psychiatry 53: 409-415.
220. 220. KOOB, G.F. & F.E. BLOOM. 1988. Cellular and molecular mechanisms of drug dependence. Science 242: 715-723.
221. 221. TRUJILLO, K.A., J.P. HERMAN, M.K.-H. SCHAFFER, A. MANSOUR, J.H. MEADOR-WOODRUFF, S.J. WATSON & H. AKIL. 1993. In Biological Basis of Substance Abuse S. G. Korenman & J. D. Barchas, Eds. :119-142. Oxford University Press. New York.
222. 222. SELF, D.W. & E.J. NESTLER. 1995. Molecular mechanisms of drug reinforcement and addiction. Ann. Rev. Neurosci. 18: 463-495.
223. 223. ZITO, K.A., G. VICKERS & D.C.S. ROBERTS. 1985. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 23: 1029-1036.
224. 224. BOZARTH, M.A. & R.A. WISE. 1986. Involvement of the ventral tegmental dopamine system in opioid and psychomolor stimulant reinforcement. NIDA Res. Monogr. 67: 190-198.
225. 225. NOEL, B.M. & A. GRATTON. 1995. Electrochemical evidence of increased dopamine transmission in prefrontal cortex and nucleus acumbens elicited by ventral tegmental μ-opioid receptor activation in freely behaving rats. Synapse 21: 110-122.
226. 226. AMALRIC, M. & G.F. KOOB. 1985. Low doses of methylnaloxonium in the nucleus accumbens antagonize hyperactivity induced by heroin in the rat. Pharmacol. Biochem. Behav. 23: 411-415.
227. 227. VACCARINO, F.J. H.O. PETTIT, F.E. BLOOM & G.F. KOOB. 1985. Effects of intracerebroventricular administration of methyl naloxonium chloride on heroin self-administration in the rat. Pharmacol. Biochem. Behav. 23: 495-498.
228. 228. JAFFE, J.H. 1990. In The Pharmacological Basis of Therapeutics. A.G. Gilman, T.W. Rall, A.S. Nies & P. Taylor, Eds. :522-573. Pergamon Press. New York
229. 229. REDMOND, D.E. & J.H. KRYSTAL. 1984. Multiple mechanisms of withdrawal from opioid drugs. Ann. Rev. Neurosci. 7: 443-478.
230. 230. NESTLER, E.J. 1992. Molecular mechanisms of drug addiction. J. Neurosci. 12: 2439-2450.
231. 231. CALVINO, B., J. LAGOWSKA & Y. BEN-ARI. 1979. Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rat. Brain Res. 177: 19-34.
232. 232. BOZARTH, M.A. & R.A. WISE. 1984. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224: 516-517.
233. 233. MALDONADO, R., L. STINUS, L.H. GOLD & G.F. KOOB. 1992. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261: 669-677.
234. 234. AGHAJANIAN, G. 1978. Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal response by clonidine. Nature 276: 186-188.
235. 235. HARRIS, H.W. & E.J. NESTLER. 1993. In The Neurobiology of Opiates. R.P.J. Hammer, Ed. :301-332. CRC Press. Ann Arbor.
236. 236. RASMUSSEN, K. & G.K. AGHAJANIAN. 1989. Withdrawal-induced activation of locus coeuleus neurons in opiate-dependent rats: attenuation by lesions of nucleus paragigantocellularis. Brain Res. 505: 346-350.
237. 237. RASMUSSEN, K., J.H. KRYSTAL & G.K. AGHAJANIAN. 1991. Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psychopharmacology 105: 508-512.
238. 238. AGHAJANIAN, G.K., J.H. KOGAN & B. MOGHADDAM. 1994. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res. 636: 126-130.
239. 239. TRUJILLO, K.A. & H. AKIL. 1994. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res. 633: 178-188.
240. 240. HIGGINS, G.A., P. NGUYEN & E.M. SELLERS. 1992. The NMDA antagonist dizocilpine (MK801) attenuate motivational as well as somatic aspects of naloxone-precipitated opioid withdrawal. Life Sci. 50: 167-172.
241. 241. KEMP, J.A. & P.D. LEESON. 1993. The glycine site of the NMDA receptor - five years on. Trends Pharmacol. Sci. 14: 20-25.
242. 242. BEM, J. & R. PECK. 1992. Dextormethorphan: an overview of safety issues. Drug Safety 7: 190-199.
243. 243. KOYUNCUOGLU, H. & B. SAYDAM. 1990. The treatment of heroin addicts with dextromethorphan: a double-blind comparision with chlorpromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28: 147-152.
244. 244. BISAGA, A., P. GIANELLI & P. POPIK. 1997. Opiate withdrawal with dextromethorphan. Am. J. Psychiatry 154: 584.
245. 245. KOSTEN, T.A., J.L. DECAPRIO & M.I. ROSEN. 1995. The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Neuropsychopharmacology 13: 323-333.
246. 246. BALL, J. & A. Ross. 1991. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcome. Springer-Verlag, Inc. New York.
247. 247. FARRELL, M., J. WARD, R. MATTICK, W. HALL, G.V. STIMSON, D. DES JARLAIS, M. GOSSOP & J. STRANG. 1994. Methadone maintenance treatment in opiate dependence: a review. Br. Med. J. 309: 997-1001.
248. 248. FARRELL, M. 1994. Opiate withdrawal. Addiction 89: 1471-1475.
249. 249. GOLD, M.S., D.E.J. REDMOND & H.D. KLEBER. 1978. Clonidine blocks acute opiate withdrawal symptoms. Lancet 2: 599-602.
250. 250. GOLD, M., D. REDMOND & H. KLEBER. 1978. Clonidine in opiate withdrawal. Lancet 1:929-930.
251. 251. GOLD, M., A. POTTASH, D. SWEENEY & H.D. KLEBER. 1980. Opiate withdrawal using clonidine. JAMA 243: 343-346.
252. 252. CHARNEY, D.S., C.E. RIORDAN, H.D. KLEBER, M. MURBURG, P. BRAVERMAN, D.E. STERNBERG, G.R. HENINGER & D.E. REDMOND. 1982. Clonidine and naltrexone: a safe, effective and rapid treatment of abrupt withdrawal from methadone. Arch. Gen. Psychiatry 39: 1327-1332.
253. 253. MASINI, E., P. BLANDINA, P. MANNAIONI & G. LUCIANI. 1981. Clonidine and naloxone for rapid opiate detoxification: comparison between treatments. Clin. Toxicol. 18: 102-26.
254. 254. CHARNEY, D.S., G.R. HENINGER & H.D. KLEBER. 1986. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. Am J. Psychiatry 143: 831-837.
255. 255. BROWER, K.J., E. MADDAHIAN, F.C. BLOW & T.P. BERESFORD. 1988. A comparison of self-reported symptoms and DSM-III-R criteria for cocaine withdrawal. Am. J. Drug Alcohol Abuse 14: 347-356.
256. 256. VINING, E., T.R. KOSTEN & H.D. KLEBER. 1988. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br. J. Addiction 83: 567-575.
257. 257. GERRA, G., A. MARCATO, R. CACCAVARI, B. FONTANESI, R. DELSIGNORE, G. FERTONANI, P. AVANZINI, P. RUSTICHELLI & M. PASSERI. 1995. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J. Subs. Abuse Treatment 12: 35-41.
258. 258. LOIMER, N., R. SCHMID, D. PRESSLICH & K. LENZ. 1989. Continuous naloxone administration suppresses opiate withdrawal symptoms in human opioid addicts during detoxification treatment. J. Psychiatric Res. 23: 81-86.
259. 259. LOIMER, N., K. LENZ, R. SCHMID & O. PRESSLICH. 1991. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am. J. Psychiatry 148: 933-935.
260. 260. LEGARDA, J. & M. GOSSOP. 1994. A 24-hour inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Dependence 35: 91-93.
261. 261. NEWMAN, R. 1987. Methadone treatment. Defining and evaluating success. N. Engl. J. Med. 317: 447-449.
262. 304. UHDE, T.W., D.E.J. REDMOND & H.D. KLEBER. 1980. Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. Psychiatry Res. 2: 37-47.
263. 305. WASHTON, A.M. & R.B. RESNICK. 1980. Clonidine for opiate detoxification: outpatient clinical trial. Am. J. Psychiatry 137: 1121-1122.
264. 306. GHODSE, H., J. MYLES & S. SMITH. 1994. Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction. Br. J. Psychiatry 165: 370-374.
265. 307. SHEARMAN, G.T., H. LAL & R.C. URSILLO. 1980. Effectiveness of lofexidine in blocking morphine-withdrawal signs in the rat. Pharmacol. Biochem. Behav. 12: 573-575.
266. 308. WASHTON, A.M. & R.B. RESNICK. 1981. Clonidine vs methadone for opiate detoxification: double-blind outpatient trials. NIDA Res. Monogr. 34: 89-94.
267. 309. GOLD, M.S., A.C. POTTASH, D.R. SWEENEY, I. EXTEIN & W.J. ANNITTO. 1982. Lofexidine blocks acute opiate withdrawal. NIDA Res. Monogr. 41: 264-268.
268. 310. WASHTON, A.M., R.B. RESNICK, J.F. PERZEL & J. GARWOOD. 1982. Opiate detoxification using lofexidine. NIDA Res. Monograph 41: 261-263.
269. 311. WYLIE, A.S. & A.M. STEWART. 1995. Lofexidine based regimen for opiate addicts [letter]. Br. J. Gen. Practice 45: 217-218.
270. 312. WILKINS, L.H., S.R. WlNTERNITZ, S. OPARIL, L.R. SMITH & H.P. DUSTAN. 1981. Lofexidine and clonidine in moderate essential hypertension. Clin. Pharmacol. Ther. 20: 752-757.
271. 313. Cox, S. & R. ALCORN. 1995. Lofexidine and opioid withdrawal [letter]. Lancet 345: 1385-1386.
272. 314. DOXEY, J. 1979. Pre- and postsynaptic effects of alpha-agonists in the anococcygeus muscle of the pithed rat. Eur. J. Pharmacol. 54: 185-189.
273. 315. SCHUBERT, H., W.W. FLEISCHHACKER, U. MEISE & C. THEOHAR. 1984. Preliminary results of guanfacine treatment of acute opiate withdrawal. Am. J. Psychiatry 141: 1271-1273.
274. 316. MUGA, R., J. TOR, J. FORTEZA-REI, C. JACAS, J. ALTES & L. MESTRE. 1990. Comparative effectiveness of alpha-2 adrenergic agonists (clonidine-guanfacine) in the hospital detoxification of opiate addicts [in Spanish]. Med. Clin. (Barc) 94: 169-172.
275. 317. SAN, L., T. FERNANDEZ, J. CAMI & M. GOSSOP. 1994. Efficacy of methadone versus methadone and guanfacine in the detoxification of heroin-addicted patients. J. Subst. Abuse Treat. 11: 463-469.
276. 318. PRESTON, K.L. & D.R. JASINSKI. 1991. Abuse liability of opioid agonist-antagonists in humans. Drug Alcohol Dependence 28: 49-82.
277. 319. O'CONNOR, P.G., K.M. CARROLL, J.M. SHI, R.S. SCHOTTENFELD, T.R. KOSTEN & B.J. ROUNSAVILLE. 1997. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann. Internal Med. 127: 526-530.
278. 320. CHESKIN, L.J., P.J. FUDALA & R.E. JOHNSON. 1994. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Dependence 36: 115-121.
279. 321. JANIRI, L., P. MANNELLI, A.M. PERSICO, A. SERRETTI & E. TEMPESTA. 1994. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Dependence 36: 139-145.
280. 322. BLACHLEY, P.H. 1973. Naloxone for diagnosis in methadone programs. JAMA 244: 334-335.
281. 323. BREWER, C., H. REZAE & C. BAILEY. 1988. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. Br. J. Psychiatry 153: 340-343.
282. 324. O'CONNOR, P.G., M.E. WAUGH, R.S. SCHOTTENFELD, I.A. DIAKOGIANNIS & B.J. ROUNSAVILLE. 1992. Ambulatory opiate detoxification and primary care: a role for the primary care physician. J. Gen. Intern. Med. 7: 532-534.
283. 325. AZATIAN, A., A. PAPIASVILLI & H. JOSEPH. 1994. A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR. J. Addictive Dis. 13: 35-52.